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Abstract
Aims: The aim of this study was to evaluate 30-day safety and efficacy outcomes of transcatheter aortic 
valve implantation (TAVI) performed with the SAPIEN 3 Ultra system.
Methods and results: The S3U registry is a physician-led, post-approval, multicentre, observational 
registry of transfemoral TAVI with the SAPIEN 3 Ultra. New features include an improved sealing skirt, 
a 14 Fr expandable sheath and a new delivery catheter. Overall, 139 consecutive patients at nine participat-
ing centres were enrolled. Mean age was 81.4±8.3 years, average STS score 3.8±2.4%. The vast majority 
(97.2%) underwent TAVI with local anaesthesia (28.8%) or conscious sedation (68.3%). Balloon predila-
tation was performed in 30 patients (21.6%), post-dilatation in three (2.2%). In-hospital, there were no 
cases of death, stroke, or conversion to open heart surgery. Major vascular complications occurred in three 
patients (2.2%), as well as major or life-threatening bleedings in three patients (2.2%). There were two 
moderate (1.4%) and no moderate/severe paravalvular leaks. Median length of stay after TAVI was three 
days (IQR 3-5 days). At 30 days, there were no deaths, MI, or strokes, and the incidence of new permanent 
pacemaker implantation was 4.4%.
Conclusions: This first multicentre international experience of transfemoral TAVI with the SAPIEN 3 


























Thirty-day SAPIEN 3 Ultra registry results
Abbreviations
EuroSCORE  European System for Cardiac Operative Risk 
Evaluation
IPE initial product evaluation
PPM permanent pacemaker
PVL paravalvular leak
SAVR surgical aortic valve replacement
S3U SAPIEN 3 Ultra
STS PROM  Society of Thoracic Surgeons predicted risk of 
mortality
TAVI transcatheter aortic valve implantation
VARC-2 Valve Academic Research Consortium-2
Introduction
Transcatheter aortic valve implantation (TAVI) represents an alter-
native to surgical aortic valve replacement (SAVR) for elderly 
patients with severe aortic stenosis (AS). Randomised clinical trials 
have demonstrated the superiority of TAVI over medical therapy in 
patients at prohibitive surgical risk, and equivalence or superiority 
over SAVR for all other surgical risk categories1-7. The field of TAVI 
is rapidly evolving, with major refinements in technology, procedural 
techniques, patient selection and biomedical engineering. With the 
development of improved devices, new approaches and new implan-
tation strategies, TAVI has become much simpler and safer. The 
first transcatheter heart valve device implanted in man in 2002 was 
a balloon-expandable device8. Since then, three further device itera-
tions have been released and approved for clinical use by Edwards 
Lifesciences (Irvine, CA, USA): the SAPIEN9, the SAPIEN XT10, 
and the SAPIEN 311. Changes have included innovations in the valve, 
the delivery system and the introducer sheath. The recently released 
SAPIEN 3 Ultra (Edwards Lifesciences) is the latest development 
whose features include an improved sealing skirt, a lower profile, 
and a simplified delivery catheter; it has gained approval for com-
mercial use in Europe and the USA. To date, there have been no 
reports documenting clinical experience with the SAPIEN 3 Ultra.
We herein report the 30-day outcomes of the S3U registry, a phy-
sician-led, post-approval multicentre, real-world observational 
registry of transfemoral TAVI with the SAPIEN 3 Ultra device.
Editorial, see page 1223
Methods
STUDY DESIGN AND PATIENT POPULATION
The SAPIEN 3 Ultra received CE mark approval in November 
2018. Since then, an initial product evaluation (IPE) phase has been 
launched, with a limited product release in selected centres across 
Europe. The IPE was terminated in December 2018. Concurrently, 
we designed a physician-led, international, multicentre, prospec-
tive registry aimed at collecting clinical, echocardiographic, pro-
cedural and outcome data of the first consecutive transfemoral 
SAPIEN 3 Ultra procedures performed within the IPE phase and 
up to February 2019. In total, nine centres participated in the study. 
The indication for TAVI was determined by a Heart Team. The 
selection of the SAPIEN 3 Ultra was based on labelled indications 
and the final decision was then left to the operators. The manu-
facturer of the SAPIEN 3 Ultra, Edwards Lifesciences, had no role 
in data collection, analysis, or manuscript drafting and did not pro-
vide any financial support for the study.
THE SAPIEN 3 ULTRA DEVICE (Figure 1)
The SAPIEN 3 Ultra retains the SAPIEN 3 cobalt-chromium 
alloy frame, with a low delivery profile and high radial strength. 
The SAPIEN 3 Ultra characteristics and differences compared to 
the SAPIEN 3 are shown in Figure 1. Briefly, the most impor-
tant changes are related to the outer skirt made from a textured 
polyethylene terephthalate (PET) and 40% higher than that of the 
SAPIEN 3 for a better final sealing. The SAPIEN 3 Ultra is avail-
able in three sizes (20, 23 and 26 mm), whereas the 29 mm valve 
is the SAPIEN 3 mounted on the Ultra delivery system. The deliv-
ery system was also modified with on-balloon valve crimping to 
streamline the procedure, eliminating the need for valve alignment 
and flex catheter retraction steps. The crossing profile is lower 
thanks to smooth tip-to-valve transition and to a shorter tapered dis-
tal tip. Finally, the Axela sheath has replaced the eSheath with new 
features. It is a 14 Fr expandable sheath for all valve sizes, includ-
ing the 29 mm SAPIEN 3. It has a hydrophilic coating for smooth 
insertion, tracking and removal. The specific design allows tran-
sient expansion and active contraction and, by means of a seamless 
design, it maintains optimal haemostasis throughout the procedure.
DEFINITIONS AND OUTCOMES
All patients had symptomatic severe native AS defined by stand-
ard criteria. Peripheral artery disease (PAD) included a history 
of intermittent claudication, previous peripheral vascular treat-
ment or documented peripheral arterial stenosis greater than 
50%. Chronic obstructive pulmonary disease was identified by 
forced expiratory volume in one second <1 litre or long-term use 
of bronchodilators, steroids or oxygen for lung disease. Chronic 
kidney disease (CKD) was identified by a glomerular filtration 
rate (GFR) <60 ml/min calculated by the Cockcroft-Gault for-
mula. The logistic EuroSCORE (European System for Cardiac 
Operative Risk Evaluation), the EuroSCORE II and the Society of 
Thoracic Surgeons predicted risk of mortality (STS PROM) score 
were reported as part of a multiparametric evaluation12,13. TAVI 
procedures were performed as per the standard practice of each 
centre. There was no standardisation of post-procedural antithrom-
botic therapy. The primary objective of the study was to evaluate 
post-procedural and 30-day safety and efficacy outcomes. All end-
points were defined according to the Valve Academic Research 
Consortium-2 (VARC-2) criteria14. The main outcomes of interest 
were device success, all-cause death, cardiac death, stroke, vascu-
lar complications, bleeding, new permanent pacemaker insertion 
and acute kidney injury. Implant success was defined as only one 
valve implanted in the proper anatomical location, and device suc-
cess according to VARC-2 criteria. All events and values collected 
are site-reported. The 30-day outcome was obtained through an 





















Descriptive statistics are reported. Continuous variables were 
expressed as mean±standard deviation (SD), or median and inter-
quartile range (IQR) when appropriate, and categorical variables 
as counts and percentages. All analyses were performed with the 
SAS 9.3 system (SAS Institute, Cary, NC, USA). Prospective 
TAVI databases were approved by the local ethics committee at 
each participating centre, and patients signed written informed 
consent for enrolment in the registry where required. The study 
protocol is in accordance with the Declaration of Helsinki. For the 
UK, data were collected as part of a mandatory UK national car-
diac audit and all patient identifiable fields were removed before 
analysis. The study complies with section 251 of the National 
Health Service Act 2006. Ethical approval was not required under 
research governance arrangements for analyses.
Results
During the study period, 139 consecutive patients underwent 
transfemoral TAVI with the SAPIEN 3 Ultra at participating cen-
tres and were enrolled in the registry. Baseline characteristics are 
reported in Table 1 and Table 2. Mean age was 81.4±8.3 years, 
54.5% were female and the average STS score was 3.8±2.4%. 
The vast majority of subjects (97.2%) underwent TAVI with local 
anaesthesia (28.8%) or by conscious sedation (68.3%) (Table 3). 
The new SAPIEN 3 Ultra valves 20, 23 or 26 mm were used in 
118 patients (84.9%), and the SAPIEN 3 29 mm with the Axela 
sheath and the Ultra delivery system in 21 (15.1%). In one patient, 
the 23 mm valve got stuck in the sheath and could not be fur-
ther advanced, requiring a sheath exchange and replacement of the 
valve with a new one. The procedure ended successfully but there 
was a flow-limiting dissection of the iliac artery that had to be 
fixed with a peripheral stent from the contralateral femoral artery. 
Re-analysis of the angio-CT scan confirmed a minimal diameter 
of 5.5 mm without relevant calcifications or tortuosity at the site 
of sheath kinking. Most of the valves were implanted without bal-
loon predilatation (78.4%). Post-dilatation was performed in three 
cases (2.2%). Mean procedural duration, from entrance to exit 
from the catheterisation laboratory, was 121±47 minutes. Implant 
success was 100%, and device success according to the VARC-2 
definition was 97.8%; there were two cases (1.4%) with moder-
ate paravalvular leak (PVL), and one case (0.7%) with a mean 
final gradient >20 mmHg and patient-prosthesis mismatch (aortic 
valve area [AVA] <0.65 cm²/m²) with a 20 mm device. In-hospital, 
there were no cases of death, stroke, or conversion to open heart 
surgery. The rate of new permanent pacemaker implantation to 
discharge was 2.2%. Major vascular complications occurred in 
three patients (2.2%), and major or life-threatening bleedings in 
three patients (2.2%). Valve haemodynamics and incidence of 
PVL are shown in Figure 2. Mean transvalvular gradients were 
19±6 mmHg for the 20 mm device, 12±4 mmHg for the 23 mm, 
Figure 1. The SAPIEN 3 Ultra device. The SAPIEN 3 Ultra presents a number of important innovations in comparison with the SAPIEN 3 
device, that involve the valve, the delivery system, and the introducer sheath. A) The valve retains the SAPIEN 3 frame and bovine pericardial 
leaflets, whereas the outer skirt (asterisk) is made of textured PET, different from the fabric seal of the SAPIEN 3 and around 40% higher. 
B) The Ultra delivery system. Highlighted, the new balloon re-designed to allow on-balloon valve crimping, obviating the need for valve 
alignment and pusher retraction before valve release. The distal end presents a smoother tip-to-valve transition and a shorter tapered distal 
tip. C) The Axela sheath: 14 Fr expandable sheath compatible with all valve sizes, engineered to allow transient expansion and active 



























AVA, cm2 0.6±0.2 1.6±0.4
AVAi, cm2/m2 0.4±0.1 1.0±0.3
Mean transvalvular gradient, mmHg 46.3±13.8 11.6±4.3
Max transvalvular gradient, mmHg 75.4±21.4 21.3±6.8
LVEF, % 57.9±10.6 58.1±10.3
LVEF <30%, n (%) 3 (2.2) 2 (1.4)
Mitral regurgitation, n (%) (n=122)
None 21 (15.1) 41 (29.5)
Mild 71 (51.1) 60 (43.2)
Moderate 31 (22.3) 15 (10.8)
Moderate-to-severe 4 (2.9) 3 (2.2)
Severe 4 (2.9) 3 (2.2)
Aortic regurgitation, n (%)
None 49 (35.3) 123 (88.5)
Mild 63 (45.3) 14 (10.1)
Moderate 17 (12.2) 2 (1.4)
Moderate-to-severe 1 (0.7) 0 (0.0)
Severe 3 (2.2) 0 (0.0)
AVA: aortic valve area; AVAi: indexed AVA; LVEF: left ventricular ejection 
fraction




Female gender, n (%) 77 (55.4)
Body mass index, kg/m2 27.3±4.6
Risk factors
Diabetes, n (%) 31 (22.3)
Hypertension, n (%) 125 (89.9)
Dyslipidaemia, n (%) 82 (59.0)
Smoking 14 (10.1)
Clinical history
Previous myocardial infarction, n (%) 25 (18.0)
Previous PCI, n (%) 46 (33.1)
Previous CABG, n (%) 9 (6.5)
Previous AVR, n (%) 0 (0.0)
Previous stroke, n (%) 11 (7.9)
Permanent pacemaker, n (%) 10 (7.2)
Comorbidities
CKD, n (%) 87 (62.6)
Dialysis, n (%) 2 (1.4)
COPD, n (%) 20 (14.4)
PAD, n (%) 13 (9.5)
CVD, n (%) 11 (7.9)
Atrial fibrillation, n (%) 35 (25.2)
Neurologic dysfunction, n (%) 6 (4.3)
Clinical presentation
Dyspnoea, n (%) 138 (99.3)
NYHA I-II 56 (40.3)
NYHA III-IV 82 (59.0)
Stable angina, n (%) 15 (10.8)
Syncope, n (%) 14 (10.1)
Pulmonary hypertension*, n (%) 9 (6.5)
Surgical risk
STS PROM, % 3.8±2.4
Logistic EuroSCORE, % 14.0±11.5
EuroSCORE II, % 4.6±4.7
Severe liver disease, n (%) 5 (3.6)
Hostile thorax, n (%) 1 (0.7)




1st degree AVB 12 (8.6%)
*Systolic pulmonary arterial pressure >60 mmHg. AVB: atrioventricular 
block; AVR: aortic valve replacement; CABG: coronary artery bypass 
graft; CKD: chronic kidney disease (GFR <60 ml/min); COPD: chronic 
obstructive pulmonary disease; CVD: cerebrovascular disease; 
EuroSCORE: European System for Cardiac Operative Risk Evaluation; 
LBBB; left bundle branch block; PAD: peripheral artery disease; 
PCI: percutaneous coronary intervention; RBBB: right bundle branch 





















































Figure 2. Haemodynamics and paravalvular regurgitation (PVL). 
A) Aortic valve area (AVA) before and after transcatheter aortic 





















11±4 mmHg for the 26 mm, and 10±4 mmHg for the 29 mm. 
In one patient, a focal leaflet thickening suggestive of thrombosis 
was detected at post-procedural echocardiography, without affect-
ing transvalvular gradients. The thickening resolved after 24 hours 
of full anticoagulation and the patient was discharged with a mean 
gradient of 10 mmHg. The median length of stay after TAVI was 
three days (IQR 3-5 days), and total hospitalisation was four days 
(IQR 2-7 days). At 30 days (Table 3, Figure 3), there were no 
deaths, MI, or strokes. Antithrombotics at discharge were dual 
antiplatelets in 58%, single antiplatelets in 7%, and oral antico-
agulation in 35% (20% direct anticoagulants, in 10% combined 
with a single antiplatelet). Three additional patients required a new 
permanent pacemaker after discharge, with an overall 30-day inci-
dence of 4.4%, and three patients were re-admitted because of 
congestive heart failure (CHF) (two paroxysmal atrial fibrillation 
[AF] with high heart rate, and one obese and severely hyperten-
sive patient who inappropriately reduced diuretics). In all patients 
who were re-admitted, echocardiography showed a well-function-
ing prosthesis.
The present patient population was compared with a control 
population composed of 139 consecutive patients treated with 
the SAPIEN 3 in the period immediately preceding the introduc-
tion of the Ultra system. The results are shown in Supplementary 
Table 1 and Supplementary Table 2. Briefly, patients treated with 
the Ultra were more frequently female with an overall lower surgi-
cal risk (e.g., STS PROM 3.8±2.4% vs 6.1±5.0%). There were no 
significant differences regarding in-hospital and 30-day outcomes.
Discussion
The current analysis reports for the first time on procedural and 
clinical outcomes in a consecutive series of patients undergoing 
transfemoral TAVI with the SAPIEN 3 Ultra in the prospective, 
international, multicentre S3U registry. The main findings are the 
following. 1) Device success was observed in 98% of the cases. 
2) In-hospital, there were no cases of death, stroke or conversion 
to open heart surgery. The PPM rate, major vascular complica-
tions and severe bleeding were below 3%, and PVL below 2% 
(none >moderate). 3) Valve haemodynamics seem comparable 
to the SAPIEN 3. 4) These results were maintained at 30 days 
with the final incidence of new PPM being 4.4%. In addition, the 
rate of post-dilatation was low, compared with modern series, at 
2.2%, perhaps indicating the better sealing characteristics of the 
improved PET skirt.
The technical changes of the SAPIEN 3 Ultra compared to the 
SAPIEN 3 were aimed at streamlining the procedure, making it 
safer, expanding the number of patients treatable using the trans-
femoral access and, most importantly, reducing the incidence of 
PVL. Our initial experience, with strict on-label use of the SAPIEN 
3 Ultra, confirms these expectations in terms of both early pro-
cedural and clinical results. Of note, general anaesthesia was not 
needed in 97.2%, balloon predilatation was performed in a minor-
ity of patients, and the median hospital length of stay after TAVI 
was three days. Most importantly, we report an exceptionally low 
incidence of all major complications both in-hospital and at 30 days 
that parallels those reported by Waksman and colleagues with the 
use of the SAPIEN 3 in low-risk patients15. However, we enrolled 
older patients (on average +8 years) and, differently from the low-
risk TAVR study, we included patients across all risk categories. 
Table 3. Procedural, in-hospital and 30-day outcomes.
Patients (n=139)
Anaesthesia/sedation status
Stand-alone local anaesthesia, n (%) 40 (28.8)
Conscious sedation, n (%) 95 (68.3)
General anaesthesia, n (%) 4 (2.9)
Valve size, n (%)
20 mm, n (%) 5 (3.6)
23 mm, n (%) 60 (43.2)
26 mm, n (%) 53 (38.1)
29 mm, n (%) 21 (15.1)
Predilatation 30 (21.6)
Device success, n (%) 136 (97.8)
Valve malposition, n (%) 0 (0.0)
Need for second valve, n (%) 0 (0.0)
Conversion to open surgery, n (%) 0 (0.0)
Cardiac tamponade, n (%) 0 (0.0)
Coronary occlusion, n (%) 0 (0.0)
Annulus rupture, n (%) 0 (0.0)
In-hospital
All-cause death, n (%) 0 (0.0)
Acute myocardial infarction, n (%) 0 (0.0)
Stroke, n (%) 0 (0.0)
Vascular complications
Major vascular complications, n (%) 3 (2.2)
Minor vascular complications, n (%) 15 (10.8)
Bleeding, n (%)
Life-threatening or disabling bleeding 1 (0.7)
Major bleeding 2 (1.4)
Minor bleeding 6 (4.3)
Acute kidney injury, n (%) 
Class 1 4 (2.9)
Class 2 0 (0.0)
Class 3 5 (3.6)
New permanent pacemaker, n (%) 3 (2.2)
New atrial fibrillation, n (%) 5 (3.6)
30-day outcome
All-cause death, n (%) 0 (0.0)
Cardiovascular death, n (%) 0 (0.0)
Stroke, n (%) 0 (0.0)
Re-hospitalisation for CHF, n (%) 3 (2.2)
New permanent pacemaker, n (%) 3 (2.2)
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There was, however, one case with a small kinking of the sheath 
that was not visible on angiography but precluded valve advance-
ment, finally causing a minor vascular complication. Whether this 
could be attributed to the play of chance or to a somewhat minor 
resistance to compression of the Axela sheath cannot be inferred 
from our data. After completion of this study, other similar cases 
have been reported worldwide. In addition, a few cases of unex-
plained balloon rupture during valve implant have been reported 
which have resulted in significant difficulty retrieving the valve 
into the catheter and withdrawing the system from the patient. In 
some cases, this was associated with vascular injury, bleeding, 
or need for surgical intervention, prompting the manufacturer to 
issue a Field Safety Notice and, later on, the US Food and Drug 
Administration (FDA) to issue a class I recall of the SAPIEN 3 
Ultra delivery system16. Following these events, the company is 
now supporting the use of the SAPIEN 3 Ultra with the Edwards 
Commander delivery system through the 14 Fr expandable eSheath.
In contrast with previous studies which have observed a higher 
rate of pacemaker requirement with the SAPIEN 34,11,17 compared 
to the SAPIEN XT trials2,10, the rate of PPM implantation in our 
study was low at 4.4% to 30 days. The reasons for this observation 
are speculative and may have occurred by chance or be explained 
by the small cohort size. Our patient population presented a low 
rate of right bundle branch block (RBBB) or conduction distur-
bances at baseline. However, it is possible that the low rate of pre-
dilatation, afforded by the lower crossing profile of the device and 
the low rate of post-dilatation, due to the improved sealing skirt 
reducing PVL, may have been contributory factors.
Limitations
This study presents some limitations that should be acknowledged. 
This is a relatively small series of SAPIEN 3 Ultra-treated patients 
performed by very experienced operators working in high-volume 
centres. Second, outcomes were self-reported by participating cen-
tres in the absence of a clinical events committee, and there was 
no core lab evaluation of echocardiographic results. While hard 
clinical endpoints such as mortality, stroke and major bleedings 
can be considered highly reliable, echocardiography and haemo-
dynamics could suffer from inter-centre differences in evaluation 
and reporting. Overall, the external validity of these results should 
be evaluated in larger studies. Importantly, however, our results 
were obtained in the learning phase of the new device for all oper-
ators, confirming the safety and the efficacy of the SAPIEN 3 
Ultra even under these circumstances. The comparison with previ-
ous-generation devices (Figure 3) is provided only for descriptive 
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Figure 3. Thirty-day clinical outcomes. Thirty-day results of the SAPIEN 3 Ultra (S3U) registry in comparison with the main trials and 




















that the improved outcomes are due only to the device because 
the time period is different, and it is well established that out-
comes are improving due to increased experience. Finally, in the 
present study, all cases were performed with the Axela sheath and 
the Ultra delivery system. After identification of potential issues 
with both devices, in most centres the SAPIEN 3 Ultra valve is 
now implanted using the SAPIEN 3 delivery kit consisting of 
the eSheath and the Commander delivery system. Although it is 
reasonable to assume consistent results with the latter combina-
tion, further testing is needed to confirm this hypothesis.
Conclusions
This first multicentre experience of patients treated by transfemo-
ral TAVI with strict on-label use of the new SAPIEN 3 Ultra trans-
catheter heart valve shows good in-hospital and 30-day clinical 
outcomes, confirming that refinements in technology and biomedi-
cal engineering may simplify and improve overall TAVI results.
Impact on daily practice
Transcatheter aortic valve implantation (TAVI) represents an 
alternative to surgical aortic valve replacement (SAVR) for 
elderly patients with severe aortic stenosis (AS) irrespective of 
surgical risk. TAVI devices are constantly being refined to address 
shortcomings of previous generations. This investigator-driven 
multicentre international study is the first to evaluate in-hos-
pital and 30-day clinical outcomes associated with the latest-
generation balloon-expandable transcatheter heart valve of the 
SAPIEN family, the SAPIEN 3 Ultra, demonstrating effective 
reduction of short-term complications and good clinical results.
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Supplementary Table 1. Univariate and multivariate analysis of association between myocardial 











Confidence interval p-value 
Univariate analysis 
 
Mid and/or distal vessel 
myocardial bridging 
1.50 1.09 – 2.06 0.012* 
Multivariate analysis* 
 
Mid and/or distal vessel 
myocardial bridging 
1.44 1.04 – 2.00 0.029* 
Age (per increase in age by 1 
year) 
0.99 0.98 – 1.00 0.068 
Male sex 1.64 1.30 – 2.09 <0.001* 
Current smoker  
 
(vs never smoker) 
 








0.85 – 1.81 
 







Hypertension 0.90 0.71 – 1.15 
 
0.417 
Diabetes mellitus 0.89 0.59 – 1.32 
 
0.550 
Hyperlipidaemia 1.26 1.00 – 1.60 
 
0.054 
History of vascular disease 1.13 0.74 – 1.72 
 
0.574 
* Multivariate analysis adjusted for age, sex, smoking status, hypertension, diabetes mellitus, 




Supplementary Table 2. Univariate and multivariate analysis of association between myocardial 









Confidence interval p-value 
Univariate analysis 
 
Myocardial bridging 1.31 0.97 – 1.76  0.075 
Multivariate analysis* 
 
Myocardial bridging 1.34 1.00 – 1.82 0.050* 
Age (per increase in age by 1 
year) 
0.98 0.98 – 0.99 0.001* 
 
Male sex 1.24 0.99 – 1.55 0.063 
Current smoker  
 
(vs never smoker) 
 








0.41 – 0.82 
 








Hypertension 1.00 0.79 – 1.26 0.99 
Diabetes mellitus 1.42 0.97 – 2.07 0.073 
Hyperlipidaemia 0.94 0.75 – 1.18 
 
0.618 
History of vascular disease 1.01 0.68 – 1.49 0.972 
* Multivariate analysis adjusted for age, sex, smoking status, hypertension, diabetes mellitus, 
hyperlipidaemia, and vascular disease. 
 
